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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death among US adults
and is projected to be the third by 2020. In anticipation of the increasing burden imposed on healthcare systems
and payers by patients with COPD, a means of identifying COPD patients who incur higher healthcare utilization
and costs is needed.
Methods: This retrospective, cross-sectional analysis of US managed care administrative claims data describes a
practical way to identify COPD patients. We analyze 7.79 million members for potential inclusion in the COPD
cohort, who were continuously eligible during a 1-year study period. A younger commercial population (7.7
million) is compared with an older Medicare population (0.115 million). We outline a novel approach to stratifying
COPD patients using “complexity” of illness, based on occurrence of claims for given comorbid conditions.
Additionally, a unique algorithm was developed to identify and stratify COPD exacerbations using claims data.
Results: A total of 42,565 commercial (median age 56 years; 51.4% female) and 8507 Medicare patients (median
75 years; 53.1% female) were identified as having COPD. Important differences were observed in comorbidities
between the younger commercial versus the older Medicare population. Stratifying by complexity, 45.0%, 33.6%,
and 21.4% of commercial patients and 36.6%, 35.8%, and 27.6% of older patients were low, moderate, and high,
respectively. A higher proportion of patients with high complexity disease experienced multiple (≥2) exacerbations
(61.7% commercial; 49.0% Medicare) than patients with moderate- (56.9%; 41.6%), or low-complexity disease (33.4%;
20.5%). Utilization of healthcare services also increased with an increase in complexity.
Conclusion: In patients with COPD identified from Medicare or commercial claims data, there is a relationship
between complexity as determined by pulmonary and non-pulmonary comorbid conditions and the prevalence of
exacerbations and utilization of healthcare services. Identification of COPD patients at highest risk of exacerbations
using complexity stratification may facilitate improved disease management by targeting those most in need of
treatment.
Background
Chronic obstructive pulmonary disease (COPD) is the
fourth leading cause of death among US adults and is
projected to be the third by 2020 [1-3], although the
disease is both preventable and treatable [4-6]. With this
projected increased burden on healthcare systems, data
describing how COPD patients are currently managed,
together with information on COPD patients’ healthcare
utilization, are needed to inform healthcare organiza-
tions and providers. A small study of 1522 COPD
patients in a health maintenance organization demon-
strated that COPD patients had healthcare utilization
and associated costs of more than twice those of age-
and sex-matched controls [7]. Similarly, a larger study
of over 100,000 patients aged ≥65 years with COPD or
asthma showed the utilization of healthcare resources by
these older COPD patients to be extremely high, both
during hospitalization and after discharge [8]. The high
prevalence of comorbidities in patients with COPD,
especially respiratory conditions and cardiovascular
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[9-11].
Because of the burden imposed on healthcare systems
and payers by patients with COPD, a means of identify-
ing COPD patients who have higher healthcare utiliza-
tion and associated higher costs is needed. The
identification and stratification of COPD patients at risk
of complications might facilitate management of these
patients, improve care, and reduce costs. Furthermore,
since COPD exacerbations, especially those requiring
hospitalization, account for significant healthcare utiliza-
tion, a method to accurately document COPD exacerba-
tions using claims data would be very useful. Finally,
comparing an older Medicare population with a working
age commercial population will provide important infor-
mation on how age influences the healthcare utilization
in patients with COPD.
The purpose of this project is to describe a unique
methodology that identifies COPD patients in a large
managed care database and documents their demo-
graphics, comorbid conditions, and COPD exacerba-
tions. We stratified these COPD patients by means of a
novel algorithm of disease complexity (high, moderate,
low complexity), used as a proxy of disease severity, and
then examined the relationship between complexity of
illness and key indicators of healthcare utilization and
exacerbations. Furthermore, data were analyzed based
on age group to determine if there are differences in
COPD patients of an older Medicare (generally ≥65
years of age) population and a younger employer-based
(< 65 years) population.
Methods
Study design and data source
This was a retrospective, cross-sectional analysis of US
managed care administrative claims data from multiple
health plans during the one-year study period, July 1,
2004, to June 30, 2005. The study population was
extracted from a dataset of 12.4 million covered lives
maintained by PharMetrics Inc (Watertown, MA, USA)
from 19 health plans across the US: 3.2 million from the
Northeast, 6.4 million from the Midwest, 1.8 million
from the South, and 0.7 million from the West. The
plans varied in size: 6 were <200,000 covered lives, 9
were between 200,001 and 1 million covered lives, and 4
were over 1 million covered lives. We evaluated the 7.79
million members who were continuously eligible during
the study period for potential inclusion in the COPD
cohort.
As differences likely exist between older and younger
individuals, data from Medicare plans were evaluated
separately from commercial health plans. The com-
mercial population represented the employer-based
managed care product offerings of Health Maintenance
Organization, Preferred Provider Organization, and
Point of Service plans. Due to the fragmentation of
healthcare claims for the population aged older than 64
years, these patients were only included in Medicare
analyses if they were continuously enrolled in a Medi-
care Risk product for the entire time span once becom-
ing 65 years old.
Identification of patients with COPD
Patients were identified as having COPD if they were
aged ≥40 years and had any one of the following:
1. One inpatient hospitalization or one emergency
room encounter with a COPD diagnosis (491.x
[chronic bronchitis], 492.x [emphysema], or 496
[chronic airway obstruction]) listed in any position
as a discharge diagnosis; or
2. Two professional claims, with different dates of
services, with a COPD diagnosis listed in any posi-
tion; or
3. A COPD-related surgical procedure (e.g. lung
volume reduction) listed on either a professional or
facility claim.
Population demographics and comorbid conditions
The age and gender were determined for patients identi-
fied with COPD from claims data. Comorbid conditions
were determined if claims data included diagnostic, pro-
cedures, and services codes (2004 ICD-9 CM, CPT-4,
and HCPCS codes, respectively) for predetermined con-
ditions (see Additional Files) during the reporting per-
iod. Condition frequencies were determined for
respiratory and for non-respiratory comorbid conditions.
Complexity
A claims-based classification of COPD complexity was
created to serve as a surrogate for COPD disease sever-
ity. Comorbid respiratory conditions and medical proce-
dures at any time during the study period were used to
assign patients to one of three disease complexity levels
(high, moderate, or low) based on selected diagnostic,
procedures and services codes (2004 ICD-9, CPT-4, and
HCPCS), as detailed in Additional File 1. Examples of
code descriptions that resulted in a patient being classi-
fied as high complexity include a claim for cor pulmo-
nale, tuberculosis, or malignant neoplasm. Examples for
moderate complexity include pneumonia, cyanosis,
bronchoscopy or dependence on supplemental oxygen.
If a COPD patient did not have any comorbid condition
for high or moderate complexity (Additional Files), they
were classified as low complexity.
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An algorithm was developed to identify and stratify
COPD exacerbations using claims data (Table 1).
Although there is controversy about the definition of a
COPD exacerbation, the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) defines an exacerba-
tion as: “an event in the natural course of the disease
(COPD) characterized by a change in the patient’sb a s e -
line dyspnea, cough and/or sputum that is beyond nor-
mal day-to-day variation, is acute in onset, and may
warrant a change in regular medication“ [1]. An exacer-
bation in this study was defined, as outlined in Table 1,
by either a primary diagnosis recorded by a medical pro-
vider and coded in claims or a medication for an oral
antibiotic commonly used for respiratory infection, or
systemic steroid received by a patient during any 14-day
time period. Exacerbation severity was classified by site
of care reflecting resource utilization.
Total exacerbations included exacerbations of any
severity (inpatient, emergency room, ambulatory by qua-
lifying diagnosis, or ambulatory supported by drug ther-
apy). Exacerbation frequency is reported for both total
and hospitalized exacerbations as percent of patients
experiencing ≥1 exacerbation(s), percent of patients
experiencing multiple (≥2) exacerbations, and number of
exacerbations/COPD patient.
Utilization of healthcare services
The healthcare services assessed in this study included tests,
procedures (including surgeries), and visits considered to be
related with COPD (see Additional File 1). The most com-
mon or relevant of these are included in this report. These
services were identified based on 2004 CPT-4 and HCPCS
codes collected in claims. Hospital admissions and emer-
gency room visits for any reason were identified based on
the presence of a facility claim for an inpatient hospital stay
or an outpatient emergency room visit.
Data analysis
DTEC™software (Pfizer, New York, NY, USA, Version
3.3) was used to integrate administrative data and
claims files, identify and stratify patients with COPD,
as well as characterize demographics, comorbidities,
and utilization of healthcare services. All of these ana-
lyses were specified prior to study initiation, and pro-
grammed in the software. These analyses, including the
algorithms for COPD complexity stratification and
exacerbation identification, were developed by a panel
of experts that included pulmonologists, outcomes
researchers and claims-based research consultants.
They are based upon information from accepted guide-
lines [1,12] but also incorporate previous experiences
of the panel in claims-based research. While DTEC™,
a proprietary software program, was used for this ana-
lysis, the algorithms for COPD disease identification
and stratification included in the software are specifi-
cally outlined and included in the body of this article
or Additional File 1 so that they may be used in other
claims querying systems.
Claims data during the 12-month study period were
analyzed, and are presented as means with standard
deviations. Categorical data are presented as numbers
and percentages. Mean data were compared using the
Student’s t-test for normally distributed values and the
Wilcoxon rank-sum test for non-normally distributed
values. Categorical data were compared between com-
mercial and Medicare populations before stratifying for
complexity, using Chi-square test. Data were analyzed
using GraphPad Prism
® statistical software (version 5.0
for Windows; GraphPad Software Inc., CA, USA).
Because of large sample sizes a p-value of 0.01 was
designated as being statistically significant for all com-
parisons. The database was compiled in accordance with
all aspects of the Health Information Portability and
Accountability Act (HIPAA) of 1996.
Table 1 Algorithm for identification and classification of exacerbations in COPD patients
Criteria for exacerbations and exacerbation types (ranked in decreasing severity):
1. Inpatient hospitalized exacerbation: an inpatient hospital stay with a primary diagnosis of COPD.
2. Emergency room visit exacerbation: an emergency room visit with a primary diagnosis of COPD.
3. Ambulatory exacerbation identified by qualifying diagnosis: an office or outpatient non-emergency room visit with any of the following
diagnosis codes in the first position: 136.3, 466-466.19, 480-486, 487.0, 490, 491.21, 491.22, 493.02, 493.12, 493.22, 493.92, 494.1, 506.0-506.3, 507-
507.8, 511.0-511.1, 512-512.8, 517.1, 518.0, 518.81, 518.82, 518.84, 770.84.
4. Ambulatory exacerbation identified by qualifying drug therapy: a pharmacy claim for the following oral antibiotics commonly used for
respiratory infections amoxicillin, beta-lactamase inhibitors, second or third-generation cephalosporins, macrolides, or doxycycline) or a claim for
systemic steroids (oral, intramuscular, or intravenous).
Application:
1. Only 1 exacerbation is attributed to a patient during any 14-day period (window).
2. The 14-day period starts with the first claim for an exacerbation of any type.
3. If the patient meets the criteria for >1 exacerbation during this 14-day window, only a single exacerbation of the most severe type is
recorded.
4. A new 14-day period is begun when a new exacerbation of any type occurs outside of the previous 14-day window.
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Population characteristics
Eligible patients from the commercial or Medicare
cohorts were identified as having COPD, and then stra-
tified by complexity as shown in Figure 1. From the
7,671,018 health plan members in the commercial data-
set, 42,565 (0.55%) met the criteria for COPD (Table 2).
The median age was 56 years and 51.4% of patients
were female. From the 115,652 health plan members in
the Medicare dataset, 8,507 (7.4%) were identified as
having COPD. In this dataset, the median age was 75
years and 53.1% were female. Although over half of both
cohorts were classified with moderate- or high complex-
ity disease, a larger proportion of the older Medicare
cohort were classified as either high or moderate com-
plexity (63.4%) compared with the younger commercial
cohort (55.0%). This was mostly due to a higher percen-
tage of high complexity patients in the Medicare cohort
(Table 2).
Comparison of the commercial and Medicare COPD
populations
Specific differences were identified in the prevalence of
comorbid conditions between the commercial and Med-
icare data sets (Table 3). For example, most cardiovascu-
lar complications were significantly less common in the
younger commercial cohort than the older Medicare
cohort, including hypertension, ischemic heart disease,
and heart failure. Those in the younger commercial
cohort were significantly more likely to have episodes of
upper respiratory tract complaints including allergic rhi-
nitis and sinusitis compared with the older Medicare
cohort, who were more likely to be diagnosed with
pneumonia. Furthermore, a significantly higher propor-
tion of patients in the younger commercial database
compared with the older Medicare dataset were docu-
mented to have current tobacco use during the study
period.
Most COPD patients in both the younger commercial
cohort and the older Medicare cohort experienced at
least 1 exacerbation during the study period (Table 4).
Patients in the commercial cohort were more likely than
Medicare members to experience an exacerbation of any
type (commercial 70.6% and Medicare 61.0%), and the
number of exacerbations per-patient in the commercial
population was higher than in the Medicare population
(2.13 vs. 1.58 per patient per year). However, patients in
the older Medicare group were more likely than com-
mercial patients to experience an exacerbation that led
to hospitalization (19.4% vs. 13.9%). Furthermore, Medi-
care patients had more hospitalized exacerbations (0.25
per patient per year) than commercial patients (0.17 per
patient per year). Multiple exacerbations (≥2) occurred
more commonly in commercial patients (47.3% of com-
mercial patients and 35.9% of Medicare patients), but
multiple hospitalized exacerbations occurred in 2.3%
and 3.6% of patients in each group, respectively.
Important differences were identified in health service
utilization between cohorts (Table 4). While nearly all of
both populations experienced at least 1 office visit con-
sultation, Medicare patients were significantly more
likely to have been hospitalized for any reason than
commercial patients. Although standard chest X-ray,
ECG’s, chest/thorax CT/MRIs, and heart echo exams
were more likely in Medicare patients, more of the
younger commercial patients had pulmonary function
testing, cardiac catheterization/coronary angiography,
and outpatient respiratory therapy. Only 39.0% of the
total cohort had pulmonary function testing during the
study period (40.0% commercial vs. 33.2% Medicare).
COPD exacerbations and health service utilization by
disease complexity
Evaluation of exacerbations by complexity group
demonstrates a general increase in the percentage of
patients experiencing total exacerbations and hospita-
lized exacerbations with increasing disease complexity in
both age cohorts (Figure 2). In addition, a higher pro-
portion of patients with high complexity disease in both
data sets experienced multiple (≥2) exacerbations (61.7%
high-complexity commercial patients; 49.0% high-
Figure 1 Stratification of patients in the study.
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(commercial 56.9%, Medicare 41.6%) or low-complexity
disease (commercial 33.4%, Medicare 20.5%), highlight-
ing the relationship between complexity and exacerba-
tions. In addition, for both the commercial and
Medicare data sets, high-complexity patients had higher
numbers of exacerbations per patient (mean 3.08 com-
mercial patients; 2.22 Medicare patients) compared with
moderate (commercial 2.47; Medicare 1.76) or low
(commercial 1.40; Medicare 0.91) complexity. The
majority of patients experiencing multiple (≥2) exacerba-
tions requiring hospitalization were classified as high
complexity (7.9% high complexity commercial patients;
10.6% Medicare), with ≤2% of moderate-complexity
patients (1.8% and 2.1%) and <1% of low-complexity
patients (0% and 0.01%), respectively.
Utilization of healthcare services was also observed to
increase with an increase in complexity (Table 5). High-
complexity patients had more than twice the pulmonary
function tests per-patient compared with low-complexity
patients, in both data sets. Patients with high complexity
illness had more office/consultation visits than those
with low complexity illness (5.7 more office/consulta-
tions in the commercial group and 3.6 more in the
Medicare data set).
Discussion
This large, retrospective, cross-sectional analysis of US
managed care administrative claims data describes a
practical method to identify COPD patients using claims
data. Furthermore, this methodology defines the com-
plexity of their illness as a proxy of disease severity, and
documents their exacerbations. The finding of a pro-
gressive increase in the prevalence of COPD exacerba-
tions and utilization of health services for COPD
patients from low to moderate to high complexity in
both the commercial and Medicare data sets validates
the utility of the complexity algorithm. Patients with
COPD classified as high complexity had the highest
health services utilization and were most likely to
experience an exacerbation.
Comorbid conditions
Our complexity classification was derived based on
claims identifying selected comorbid conditions or med-
ical procedures. Patients with COPD are typically
thought to have comorbid diseases and conditions that
contribute to the high burden of their disease
[7,10,13,14]. Our data highlight that 4-27% of COPD
patients had a respiratory comorbid condition, but up to
72% had a non-respiratory comorbid condition. Conse-
quently over half of both age cohorts were stratified as
moderate or high complexity. Our findings concur with
other data [7,10], highlighting the high incidence of
comorbidities in COPD patients. For example a study of
200 patients showed that patients with COPD had an
average of 3.7 chronic medical conditions (including
lung disease), compared with 1.8 chronic medical condi-
tions for the controls [7]. Furthermore, a review by Sin
et al., highlighted that a large proportion of patients
Table 2 Demographic characteristics for the commercial and Medicare data sets, stratified by complexity
Commercial dataset Medicare dataset
All
patients
Low
complexity
Moderate
complexity
High
complexity
All
patients
Low
complexity
Moderate
complexity
High
complexity
(n =
42,565)
(n = 19,154;
45.0%)
(n = 14,290;
33.6%)
(n = 9,121;
21.4%)
(n =
8,507)
(n = 3,110;
36.6%)
(n = 3,047;
35.8%)
(n = 2,350;
27.6%)
Parameter
Age, years
Median 56 56 57 57 75 75 75 75
Age categories, n (% of column)
40-44
years
2,960 (7.0) 1,471 (7.68) 917 (6.42) 572 (6.27) 15 (0.2) 2 (0.1) 10 (0.3) 3 (0.1)
45-54
years
14,432
(33.9)
6,704 (35.0) 4,817 (33.7) 2,911 (31.9) 125 (1.5) 40 (1.3) 41 (1.3) 44 (1.9)
55-64
years
25,173
(59.1)
10,979 (57.3) 8,556 (59.9) 5,638 (61.8) 460 (5.4) 134 (4.3) 171 (5.6) 155 (6.6)
65-74
years
0 (0) 0 (0) 0 (0) 0 (0) 3,367
(39.6)
1,295 (41.6) 1,176 (38.6) 896 (38.1)
75-84
years
0 (0) 0 (0) 0 (0) 0 (0) 3,625
(42.6)
1,324 (42.6) 1,296 (42.5) 1,005 (42.8)
≥85
years
0 (0) 0 (0) 0 (0) 0 (0) 915 (10.8) 315 (10.1) 353 (11.6) 247 (10.5)
Gender (%, of column)
Female 51.4 49.2 54.7 50.7 53.1 53.6 54.2 51.2
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depression, muscle wasting, reduced fat-free mass,
osteopenia, and chronic infections [10].
Comorbidities in COPD patients contribute towards
the high morbidity and mortality [14]. In particular, car-
diovascular disease is a common cause of death in
COPD patients [15-17], with co-prevalence estimates in
COPD patients of 43% (mean age 68.8 years [14]) and
45% (mean age 67.5 years [7]). In the present study,
similar prevalence estimates for key cardiovascular dis-
ease risk factors were found in commercial patients
(median age 56 years), although higher prevalence in
older patients, with 72% of the Medicare cohort (median
age 75 years) having comorbid hypertension and 47%
having dyslipidemia. In addition, heart failure (HF) is a
risk factor for mortality in COPD patients, and particu-
larly in those experiencing an exacerbation [14,18]. In
the present study nearly 40% of the older Medicare
cohort had HF, a proportion in agreement with a study
of a similarly aged population among whom 40% had
HF [18].
Exacerbations
Our study describes a practical way to identify COPD
exacerbations using claims data, and to classify them by
site of care. In the current study the majority of
patients, regardless of age, experienced COPD exacerba-
tions, which often involved hospitalization or an emer-
gency room visit. Others have used healthcare
utilization to define the staging of COPD exacerbations,
in order to incorporate those parameters considered
most appropriate to base sub-classification [19]. Indeed,
classification of an exacerbation as mild, moderate, or
severe was deemed to be strongly related to the patient’s
underlying condition [19]. Accordingly, for a patient
Table 4 Prevalence (%) of patients experiencing ≥1
exacerbation and health services utilization among COPD
patients in the commercial and Medicare datasets*
Parameter, Commercial
dataset
(n = 42,565)
Medicare
dataset
(n =
8,507)
Exacerbations
Inpatient hospitalization 13.9 19.4
ER visit exacerbation 4.5 4.5
Ambulatory exacerbations, with
qualifying diagnosis
35.6 27.6
Ambulatory exacerbations supported
by qualifying drug therapy
49.6 34.0
Total exacerbations (any of the above
types)
70.6 61.0
Health services
Hospitalization (any reason) 39.2 52.9
Office consultation/visit 98.7 96.4
Standard chest X-rays 73.1 74.8
Electrocardiogram 56.9 68.9
Pulmonary function testing 40.0 33.2
Respiratory-related equipment/supplies 26.0 35.7
Heart echo exam 25.8 40.1
Chest/thorax CT/MRI 23.6 26.6
Cardiovascular stress test 19.2 19.2
Respiratory/inhalation therapy 19.1 14.9
Cardiac catheterization/coronary
angiography
9.3 8.0
Bone density study 7.8 7.6
Sleep studies 5.4 2.0
Disease management program 4.1 0
Bronchoscopy 3.9 3.6
*All of the differences comparing prevalence of comorbid conditions between
commercial and Medicare populations were significant (p < 0.01), using two-
tailed, chi-squared analysis, except for those indicated by italic text.
Table 3 Prevalence (%) of comorbid conditions in COPD
patients from commercial and Medicare data sets*
Commercial
dataset
(n = 42,565)
Medicare
dataset
(n = 8,507)
Respiratory, %
Asthma 27.1 21.3
Sinusitis 21.2 8.4
Current tobacco use 19.0 7.5
Pneumonia 18.8 26.3
Allergic rhinitis 12.9 6.8
Sleep apnea 12.5 5.9
Respiratory failure 8.0 13.0
Pleurisy/pleural effusion 7.5 11.6
Pulmonary edema 5.7 11.2
Pulmonary heart disease 4.2 7.0
Respiratory tract cancer 4.2 7.1
Non-respiratory, %
Hypertension 55.2 71.6
Dyslipidemia 48.2 47.3
Ischemic heart disease/angina 26.5 44.7
Diabetes 21.9 28.8
Heart rhythm conduction
disturbance
20.4 38.9
Depression 14.5 9.4
Heart failure 14.4 33.8
Kidney disease/abnormal kidney
function
11.5 21.9
Obesity 8.2 4.8
Cerebrovascular disease 9.2 20.5
Osteoporosis/decreased bone
density
5.7 11.7
Myocardial Infarction (new or
history)
4.1 7.1
*All of the differences comparing prevalence of comorbid conditions between
commercial and Medicare populations were significant (p < 0.01), using two-
tailed, chi-squared analysis, except for those indicated by italic text.
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may present as a moderate-to-severe exacerbation
because it necessitates physician intervention and
increased healthcare utilization [19]. We stratified
exacerbations by the site of care (inpatient hospitaliza-
tion, emergency room visit, and ambulatory exacerba-
tions), which enabled more detailed information
regarding the patients’ site of healthcare utilization to be
accounted for. This is also somewhat similar to symp-
tom-based classification of exacerbations often used in
clinical trials which capture patients whose condition
has changed enough to require a change in treatment,
an emergency room visit, or hospitalization.
Patients in the older Medicare cohort were more likely
to have moderate- or high complexity illness compared
with the younger commercial dataset. This might be
expected, as lung function and general health declines
with age [20,21]. Our data also highlight that these
patients qualified as high complexity were more likely to
have multiple exacerbations and exacerbations requiring
hospitalization compared with those of moderate or low
complexity. As data were de-identified, it was not
possible to confirm exacerbation information with corre-
sponding medical records or clinical observations in this
analysis. However, by distinguishing these high-risk
patients from the overall COPD population, it might be
ultimately possible to specifically target high-risk
patients to limit the severity of their exacerbations with
appropriate adjustment of therapy and/or monitoring of
their comorbid conditions.
Although this study did not evaluate healthcare costs,
the data generated could be used for future economic
analyses and modeling. Others have reported the eco-
nomic burden that exacerbations place on the healthcare
system. Indeed, the estimated costs of exacerbations
have been found to vary widely across studies from
approx. $88 to $7,757 per exacerbation (2007 US dol-
lars) [22]. Furthermore, exacerbations accounted for
35%-45% of the total per capita healthcare costs for
COPD in one study, with costs increasing with severity
of exacerbations [23]. Accordingly, investigating how
actual or projected costs of COPD may change through
identification of patients by exacerbations and subse-
quent stratification by complexity, as described in the
present study, would be an interesting area to investi-
gate further.
Utilization of healthcare services
We identified groups of COPD patients that are high
users of healthcare services. For example, over half of
the Medicare COPD patients and almost 40% of com-
mercial COPD patients were hospitalized at least once
for any reason in a 1-year period. Evidence of high out-
patient utilization is characterized by the finding that
virtually all patients in both populations (≥96%) had at
least 1 office visit/consultation with a mean of over 10
per patient during the year. Furthermore, our method of
stratifying patients found differential healthcare utiliza-
tion; our high complexity patients had the highest health
services utilization across almost all of the services mon-
itored. As our method of stratifying patients to high and
medium complexity was dependent on their comorbid
conditions and the procedures they received, it is logical
to expect that these patients had higher utilization com-
pared with those of low complexity.
We do not know if our high complexity group had
higher healthcare utilization in subsequent years, and
this would be an important subject for future investiga-
tions. Interestingly, although GOLD guidelines state that
lung function testing with spirometry is essential for the
diagnosis and management of COPD, and indeed can
provide a useful description of the severity of pathologi-
cal changes in COPD [1], less than half of the popula-
tion had a pulmonary function test carried out during
the study year.
(A): Commercial cohort  
 
(B): Medicare cohort  
 
†Any exacerbation includes inpatient hospitalized exacerbation, an ambulatory exacerbation with 
qualifying diagnosis or ambulatory exacerbation with qualifying drug therapy. 
Figure 2 COPD Patients Registering an inpatient exacerbation
or experiencing any exacerbation, stratified by complexity, for
(A) commercial, and (B) Medicare cohorts.
†Any exacerbation
includes inpatient hospitalized exacerbation, an ambulatory
exacerbation with qualifying diagnosis or ambulatory exacerbation
with qualifying drug therapy.
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important limitations. These analyses are retrospective
and descriptive in nature; there were no control groups.
The large sample sizes resulted in statistically significant
differences between cohorts that may not be clinically
significant. However, we adjusted for the large sample
size by defining significance as p < 0.01, rather than the
conventional level of p < 0.05. Administrative claims
data are primarily generated for reimbursement pur-
poses rather than research purposes. Consequently, the
accuracy of claims data is dependent on the precision
and timing of the coding associated with their use. As
such, some comorbid conditions, such as obesity and
tobacco use, are often under-reported in claims data
and likely are under-reported here as well. Furthermore,
confusion over the differential diagnosis of asthma and
COPD could have led to some patients in our COPD
cohorts who actually had asthma rather than COPD. In
fact, at least 1 claim with a diagnosis of asthma was
recorded in 27% and 21% of the commercial and Medi-
care COPD cohorts, respectively. Findings of cross-sec-
tional studies have shown a similar overlap of up to 30%
between people who have a clinical diagnosis of COPD
and asthma [24]. While some of these claims could
represent coexisting asthma and COPD, the potential
for diagnosis coding errors needs to be taken into con-
sideration. The possibility that other respiratory condi-
tions, such as bronchiectases, hypoventilation-obesity, or
overlap syndrome, were miscoded as COPD should also
be considered. Furthermore, there is a possibility that
asthma attacks were miscoded as COPD exacerbations.
Because the study period was limited to 1 year, it is pos-
sible for the data to provide false positives or negatives
in the population selection criteria and overstate or
Table 5 Proportion (%) of COPD patients in the Medicare and Commercial Cohorts Using ≥1 healthcare services, and
mean number of each form of health service utilized per COPD patient, stratified by complexity of illness
Commercial dataset Medicare dataset
Service, % (mean per patient) Low
complexity
Moderate
complexity
High
complexity
Low
complexity
Moderate
complexity
High
complexity
(n = 19,154;
45.0%)
(n = 14,290;
33.6%)
(n = 9,121;
21.4%)
(n = 3,110;
36.6%)
(n = 3,047;
35.8%)
(n = 2,350;
27.6%)
Office consultation/visit 98.9 98.6 98.6 97.3 95.4 96.4
Mean per patient 9.41 11.52 15.06 10.3 10.9 13.9
Standard chest X-ray 62.7 77.5 88.0 63.1 74.5 90.9
Mean per patient 1.25 2.45 6.37 1.3 2.4 6.3
Electrocardiogram 50.6 56.5 71.0 60.7 66.3 83.1
Mean per patient 1.14 1.57 2.63 1.6 2.2 3.9
Pulmonary function 34.3 40.4 51.4 26.7 32.8 42.5
Mean per patient 1.02 1.47 2.33 0.9 1.3 1.9
Respiratory-related equipment/
supplies
5.41 36.0 53.3 8.52 50.4 52.5
Mean per patient 0.27 4.63 8.63 0.9 9.5 10.8
Heart echo exam 18.4 25.5 41.9 29.4 37.6 57.7
Mean per patient 0.68 1.06 2.00 1.1 1.5 2.8
Chest/thorax CT/MRI 11.4 24.5 47.8 12.5 23.6 49.1
Mean per patient 0.19 0.42 1.14 0.2 0.4 1.0
Cardiovascular stress test 18.7 18.6 21.3 18.7 17.8 21.9
Mean per patient 0.32 0.32 0.38 0.3 0.3 0.4
Outpatient respiratory therapy
services
10.3 25.7 27.1 4.95 20.6 20.7
Mean per patient 0.16 0.69 1.00 0.1 1.3 1.4
Cardiac catheterization/coronary
angiography
7.48 8.92 13.8 5.05 7.68 12.4
Mean per patient 0.51 0.61 0.94 0.3 0.5 0.8
Sleep studies 1.72 4.43 14.7 0.35 1.51 4.68
Mean per patient 0.03 0.08 0.31 0 0 0.1
Bronchoscopy 0.32 2.88 13.2 0.16 2.0 10.1
Mean per patient 0 0.07 0.35 0 0 0.2
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sidered. In this case, individuals with COPD who did
not have COPD-related claims within the observation
period are not included in the analysis. Since these
patients are likely to have less severe disease, this would
result in the overall prevalence of COPD being under-
stated, while the burden per patient with COPD over-
stated. On the other hand, because patients had to be
continuously enrolled during the entire study year to be
eligible for inclusion in this cross-sectional analysis,
those who either left their health plan or died were
excluded from the analysis. Excluding those who died
could have removed those who were most ill and uti-
lized the most healthcare resources. This could be espe-
cially important in the elderly cohort.
It is also possible that differences in exacerbations and
healthcare utilization between different groups could be
due to unrecognized confounders, such as duration of
COPD, current smoking status, and type and duration
of medication use. In addition, given that the study was
a cross-sectional analysis, no cause and effect analyses
could be conducted. We broadly compared an older
Medicare population with a younger employer-based
commercial population, although 7% of the Medicare
population was <65 years and we were unable to extract
these patients from the data set. However, as over 90%
of the patients were ≥65 years we feel our observations
provide useful information on how age influences the
burden of COPD on managed care resources
Despite these limitations, the methodology presented
here provides a practical way for healthcare providers to
identify and stratify COPD patients and identify those
experiencing exacerbations within a large managed care
database. In turn, this might help healthcare providers
prioritize patients at risk for future exacerbations and
resource utilization, to help ensure that those COPD
patients with the greatest need for close monitoring
receive optimal care.
Conclusions
We present a unique and practical method for identify-
ing patients with COPD, determining disease severity -
as “complexity of illness” - and documenting exacerba-
tions using claims data. Our data highlight important
differences in comorbidities, exacerbations, and health-
care utilizations in older (aged ≥65 years) compared
with younger (aged <65 years) COPD patients. Further-
more, by stratifying COPD patients based on diagnostic,
procedures, and services codes, we have demonstrated
that patients stratified as having high- or moderate com-
plexity disease experienced a higher number of exacer-
bations than those with low complexity disease.
Additionally, by stratifying by complexity of illness we
show linearity between complexity of illness and utiliza-
tion of healthcare services and hospitalizations.
Identification of COPD patients at higher risk of com-
plications using complexity stratification and/or identify-
ing those experiencing exacerbations may serve to
improve patient management, and ultimately reduce the
burden of disease to the patient, and to the healthcare
systems supporting them.
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